Aida

L(+)-AP-3 L-CGG-I (5>4C3HPG S(+)-MCPA MSOP Other

ACEA-1011 Riluzole d (-)-2-Amino-7-phosphonoheptanoic acid Cii-4-phosphonomethyl-2-piperidine carboxylic acid

3-(2-Carboxypiperazin-4-yl)-propyl-l-phosphonic acid 3S,4aR,6S,8aR,-6-Phosphonomethyl-decahydroisoquinoline-3-carboxylic acid 6-(1(2)ff-Tetrazol-5-yl)methyldecahydroisoquinoline-3-carboxylic acid

6-Phosphonomethyl-decahydroisoquinoline-3-carboxylic acid 2-Amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid 2R,4R,5S-2-Amino-4, 5-(1,2-cyclohenyl)-7-phophonoheptanoic acid

5-Aza-7-chloro-4-hydroxy-3-(m-phenoxyphenyl)quinoline-2(1ff)-one 5-Nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione 5-Nitro-6,7-dibromo-1,4-dihydro-2,3-quinoxalinedione 5-Nitro-6,7-dimethyl-1,4-dihydro-2,3-quinoxalinedione

1-Amino-1-cyclopropane carboxylic acid

7-Chlorokynurenic acid 6,7-Dichloroquinoxaline-2,3-dione R(+)-3-Amino-1-hydroxypyrrolidin-2-one

5-Aminocarbonyl-10,11-dihydro-5h-dibenzo[a,d]cyclohepten-5,10-imine (+)-3-Hydroxy-N-methyl morphinan

2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone 3,5-Dimethyladamantan-1-amine

(5R, 10S)-(+)-5-methyl-10,11-dihydro-5#-dibenzo[a,^cyclohepten-5,10-imine

1-(1-Phenylcyclohexyl)piperidine

N-Allyl-normetazocine

1-[1-(2-Thienyl)cyclohexyl]piperidine

(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-phenylpiperidino)-1-propanol a-(4-Chlorophenyl)-4-[(4-fluorophenyl) methyl]-1-piperidine ethanol

4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone

2-(4-Benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol

1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-5_ff-2,3-benzodiazepine 1,2,3,4-Tetrahydro-6-nitro-2,3-dioxo-benzo[/]quinoxaline-7-sulfonamide

1-Aminoindan-1,5-dicarboxylic acid

2-Amino-3-phosphonopropionic acid (2S, 1'S, )-2'-(Carboxycyclopropyl)-glycine (S)-4-Carboxy-3-hydroxyphenylglycine (S)-a-Methyl-3-carboxyphenylalanine a-Methylserine-O-phosphate

5-Chloro-7-trifluoromethyl-1,2,3,4-tetrahydroquinoxaline-2,3,-dione 2-Amino-6-(trifluoromethoxy)-benzothiazole clinically unacceptable side effects, although they are generally less severe than those produced by channel blockers (11,12). In contrast, antagonists that interact with other binding sites on the NMDA receptor complex, such as the glycine and allosteric modulatory sites, tend to be associated with the fewest problematic side effects (12-14). One reason for this may be that many channel blockers act like a switch to turn the receptor "off' when the ionophore is blocked. Given the extensive

Allosteric site Glycine site: Ifenprodil

ACEA 1021 Co 101022

Ion channel site

Kicking Fear And Anxiety To The Curb

Kicking Fear And Anxiety To The Curb

Kicking Fear And Anxiety To The Curb Can Have Amazing Benefits For Your Life And Success. Learn About Calming Down And Gain Power By Learning Ways To Become Peaceful And Create Amazing Results.

Get My Free Ebook


Post a comment